Although we used plasma samples containing an unknown amount of wildtype contamination, we observed a fall in ctDNA levels of both ESR1 and PIK3CA or AKT1 mutations after 1 cycle of treatment, suggesting that this fall in ctDNA load represents a decreased tumor load rather than pre-analytical variation. The gene discussed is AKT1; the disease is neoplasm.